Entity

Time filter

Source Type

Quinto di Treviso, Italy

Dei Tos A.P.,General Hospital of Treviso
Histopathology | Year: 2014

Liposarcomas represent the most common histotype among soft tissue sarcomas. However, liposarcomas in fact constitute a heterogeneous group of distinctive lesions that pose several diagnostic difficulties. The current World Health Organization classification of soft tissue and bone tumours recognizes four major liposarcoma subtypes: (i) atypical lipomatous tumour/well-differentiated liposarcoma; (ii) de-differentiated liposarcoma; (iii) myxoid liposarcoma; and (iv) pleomorphic liposarcoma. These four main subgroups are characterized by distinctive morphologies, unique genetic findings as well as distinct clinical behaviour. Accurate classification requires the integration of morphological, immunohistochemical and (in selected situations) genetic findings, and is essential for providing patients with the best available treatments. This review will focus upon the main diagnostic pitfalls encountered in the routine diagnosis of liposarcoma, underlining the diagnostic value of combining morphology with cytogenetics and molecular genetics. © 2013 John Wiley & Sons Ltd. Source


Gallucci M.,Cognitive Impairment Center | Zanardo A.,General Hospital of Treviso | Bendini M.,Neuroradiology Unit | Di Paola F.,Neuroradiology Unit | And 2 more authors.
Journal of Alzheimer's Disease | Year: 2014

Background: The role of folate and homocysteine in brain atrophy associated with Alzheimer's disease is not completely understood. Objective: The aim of this study was to investigate the relationships between serum folate and homocysteine levels and the degree of cortical-subcortical and hippocampal atrophy in a first relatively preliminary sample of the Treviso Dementia (TREDEM) study using a potent data mining method. Methods: Physiological data, biochemical parameters, clinical assessment data, brain atrophy severity assessed with CT scans, and neuropsycological and disability data were assessed in a group of 232 outpatients (93 men and 139 women, aged 40.2-100 years) enrolled in the TREDEM study carried out in Treviso (Italy). A semantic connectivity map obtained through the Auto-CM system, a fourth generation artificial neural network (ANN), was used to offer some insight regarding the complex biological connections between the studied variables and the degree of brain atrophy. Results: Close associations between low serum folate levels and severe cortical-subcortical atrophy along with severe hippocampal atrophy measured by the width of the temporal horns of lateral ventricles were found. We also showed an association between high homocysteine levels and severe cortical-subcortical and hippocampal atrophy. Conclusion: The role of folate, which is inversely associated with the severity of brain atrophy, was confirmed. Our results also confirm the association between high homocysteine levels and severe cortical-subcortical and hippocampal atrophy. Auto-CM ANN is able to highlight associations sometimes visible only in longitudinal studies through intelligent data mining of a cross-sectional study. © 2014 - IOS Press and the authors. All rights reserved. Source


Stacchiotti S.,Adult Sarcoma Medical Oncology Unit | Negri T.,Experimental Molecular Pathology Unit | Libertini M.,Adult Sarcoma Medical Oncology Unit | Palassini E.,Adult Sarcoma Medical Oncology Unit | And 7 more authors.
Annals of Oncology | Year: 2012

Background: To report on sunitinib activity in a retrospective series of 35 solitary fibrous tumor (SFT) treated at a single institution. Patients and methods: From April 2008, 35 patients with progressive advanced SFT (male/female: 20/15; mean age: 58 years; meningeal/extrameningeal: 6/29; locally advanced/metastatic: 15/20; prior chemotherapy: 25) were treated, on an individual use basis, with continuous-dosing sunitinib 37.5 mg/day. Platelet-derived growth factor receptor beta (PDGFRB) and vascular endothelial growth factor receptor 2 (VEGFR2) status were assessed by immunohistochemistry and, in a subgroup of patients, by real time PCR. Results: Thirty-one patients were assessable for response by RECIST (one early death; three early interruptions). Best responses were 2 partial response (PR), 16 stable disease, 13 progressive disease. A <30% decrease in size was observed in three patients. Fourteen of 29 patients assessable by Choi criteria had a PR. Median progression-free survival by RECIST was 6 months (range 1-22). In two of six patients, resistance to sunitinib was overcome by increasing sunitinib to 50 mg/day. PDGFRB and/or VEGFR2 were positive in all cases and not predictive of response; a less aggressive morphology corresponded to an increased response rate (53% PR by Choi in the malignant SFT, 20% PR in the pleomorphic/dedifferentiated SFT). Conclusions: Sunitinib is active in SFT. Response can be long-lasting. © The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. Source


Sanfilippo R.,Adult Sarcoma Medical Oncology Unit | Grosso F.,Adult Sarcoma Medical Oncology Unit | Jones R.L.,Sarcoma Unit | Banerjee S.,Sarcoma Unit | And 6 more authors.
Gynecologic Oncology | Year: 2011

Background: Treatment options for patients with metastatic uterine leiomyosarcoma are limited. Over the last few years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to look at the efficacy of trabectedin in the subgroup of uterine leiomyosarcoma. Patients and methods: A retrospective analysis was carried out on patients with uterine leiomyosarcoma treated with trabectedin at two reference sarcoma centers between 2000 and 2010. Radiological response, progression-free and overall survival, as well as serious and unexpected adverse events, were assessed. Results: Sixty-six patients with metastatic uterine leiomyosarcoma were identified. The median number of previous chemotherapy regimens was 3 (range 1-5). Eleven patients (16%) achieved a partial response and 23 (35%) had a stable disease. The progression-free survival of the entire cohort was 3.3 months (CI 95% 2-5), and the progression-free rate at 3 and 6 months was 53% and 33%, respectively. Conclusions: Trabectedin is a therapeutic option in the palliative approach to the metastatic uterine leiomyosarcoma patient. © 2011 Elsevier Inc. All rights reserved. Source


Angeli P.,University of Padua | Fasolato S.,University of Padua | Mazza E.,University of Padua | Okolicsanyi L.,General Hospital of Treviso | And 7 more authors.
Gut | Year: 2010

Objective: The aim of the study was to compare sequential versus combined diuretic therapy in patients with cirrhosis, moderate ascites and without renal failure. Design: One hundred patients were randomly assigned to the two diuretic treatments. The sequential treatment provided potassium canrenoate at the initial dose of 200 mg/day, then increased to 400 mg/day. Nonresponders were treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/ day, then increased to 150 mg/day. The combined treatment provided the initial dose of 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased to 400 mg/day and 150 mg/day, respectively. Results: Most patients who received sequential treatment responded to potassium canrenoate alone (19% to 200 mg/day and 52.63% to 400 mg/day, respectively). Most patients who received the combined treatment responded to the first two steps (40% to the first step and 50% to the second, ie, 400 mg/day of potassium canrenoate plus 100 mg/day of furosemide). Adverse effects (38% vs 20%, p<0.05), in particular, hyperkalaemia (18% vs 4%, p<0.05), were more frequent in patients who received sequential therapy. As a consequence, the per cent of patients who resolved ascites without changing the effective diuretic step was higher in those who received the combined treatment (56% vs 76%, p<0.05). Conclusions: The combined diuretic treatment is preferable to the sequential one in the treatment of moderate ascites in patients with cirrhosis and without renal failure. NCT00741663. This work is an open randomised clinical trial. Source

Discover hidden collaborations